Anxiety as a predictor of treatment outcome in children and adolescents with depression

Amy Cheung, Taryn Mayes, Anthony Levitt, Ayal Schaffer, Erin Michalak, Alex Kiss, Graham Emslie

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: The aim of this study was to examine the impact of co-morbid illnesses on treatment outcomes in depressed children and adolescents aged 7-17 who were treated with fluoxetine. Method: This data set was drawn from two large clinical trials involving children and adolescents with depression. Subjects with a diagnosis of major depressive disorder and depressive symptoms of at least moderate severity as defined by a Children's Depression Rating Score, Revised (CDRS-R) total score ≥40 and a Clinical Global Impressions-Severity (CGI-S) rating ≥4 were included. Subjects were randomized to receive fluoxetine or placebo over an 8-week period. Predictor analyses examining two primary outcomes were conducted: (1) Response based on Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2, and (2) remission based on CDRS-R score of ≤28. Logistic regression models were run to assess whether anxiety disorders were a predictor of response or remission. Result: A total of 309 study participants were included. The only factor found to influence response was treatment with fluoxetine (p? =? 0.022, odds ratio [OR]? =? 2.08, 95% confidence interval [CI] 1.30, 3.31). Several factors were found to influence remission: Treatment with fluoxetine (p? <? 0.0001, OR? =? 3.17, 95% CI 1.80, 5.57), gender (p? =? 0.024, OR? =? 1.90, 95% CI 1.09, 3.30), and number of co-morbid diagnoses (p? =? 0.026, OR 0.73, 95% CI 0.55, 0.96). Conclusion: Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
JournalJournal of Child and Adolescent Psychopharmacology
Volume20
Issue number3
DOIs
StatePublished - Jun 1 2010

Fingerprint

Fluoxetine
Anxiety
Depression
Odds Ratio
Confidence Intervals
Anxiety Disorders
Logistic Models
Major Depressive Disorder
Placebos
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Anxiety as a predictor of treatment outcome in children and adolescents with depression. / Cheung, Amy; Mayes, Taryn; Levitt, Anthony; Schaffer, Ayal; Michalak, Erin; Kiss, Alex; Emslie, Graham.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 20, No. 3, 01.06.2010, p. 211-216.

Research output: Contribution to journalArticle

Cheung, Amy ; Mayes, Taryn ; Levitt, Anthony ; Schaffer, Ayal ; Michalak, Erin ; Kiss, Alex ; Emslie, Graham. / Anxiety as a predictor of treatment outcome in children and adolescents with depression. In: Journal of Child and Adolescent Psychopharmacology. 2010 ; Vol. 20, No. 3. pp. 211-216.
@article{7f3165f2ed914238936504455d8eb8ce,
title = "Anxiety as a predictor of treatment outcome in children and adolescents with depression",
abstract = "Objective: The aim of this study was to examine the impact of co-morbid illnesses on treatment outcomes in depressed children and adolescents aged 7-17 who were treated with fluoxetine. Method: This data set was drawn from two large clinical trials involving children and adolescents with depression. Subjects with a diagnosis of major depressive disorder and depressive symptoms of at least moderate severity as defined by a Children's Depression Rating Score, Revised (CDRS-R) total score ≥40 and a Clinical Global Impressions-Severity (CGI-S) rating ≥4 were included. Subjects were randomized to receive fluoxetine or placebo over an 8-week period. Predictor analyses examining two primary outcomes were conducted: (1) Response based on Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2, and (2) remission based on CDRS-R score of ≤28. Logistic regression models were run to assess whether anxiety disorders were a predictor of response or remission. Result: A total of 309 study participants were included. The only factor found to influence response was treatment with fluoxetine (p? =? 0.022, odds ratio [OR]? =? 2.08, 95{\%} confidence interval [CI] 1.30, 3.31). Several factors were found to influence remission: Treatment with fluoxetine (p? <? 0.0001, OR? =? 3.17, 95{\%} CI 1.80, 5.57), gender (p? =? 0.024, OR? =? 1.90, 95{\%} CI 1.09, 3.30), and number of co-morbid diagnoses (p? =? 0.026, OR 0.73, 95{\%} CI 0.55, 0.96). Conclusion: Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine.",
author = "Amy Cheung and Taryn Mayes and Anthony Levitt and Ayal Schaffer and Erin Michalak and Alex Kiss and Graham Emslie",
year = "2010",
month = "6",
day = "1",
doi = "10.1089/cap.2010.0006",
language = "English (US)",
volume = "20",
pages = "211--216",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Anxiety as a predictor of treatment outcome in children and adolescents with depression

AU - Cheung, Amy

AU - Mayes, Taryn

AU - Levitt, Anthony

AU - Schaffer, Ayal

AU - Michalak, Erin

AU - Kiss, Alex

AU - Emslie, Graham

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Objective: The aim of this study was to examine the impact of co-morbid illnesses on treatment outcomes in depressed children and adolescents aged 7-17 who were treated with fluoxetine. Method: This data set was drawn from two large clinical trials involving children and adolescents with depression. Subjects with a diagnosis of major depressive disorder and depressive symptoms of at least moderate severity as defined by a Children's Depression Rating Score, Revised (CDRS-R) total score ≥40 and a Clinical Global Impressions-Severity (CGI-S) rating ≥4 were included. Subjects were randomized to receive fluoxetine or placebo over an 8-week period. Predictor analyses examining two primary outcomes were conducted: (1) Response based on Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2, and (2) remission based on CDRS-R score of ≤28. Logistic regression models were run to assess whether anxiety disorders were a predictor of response or remission. Result: A total of 309 study participants were included. The only factor found to influence response was treatment with fluoxetine (p? =? 0.022, odds ratio [OR]? =? 2.08, 95% confidence interval [CI] 1.30, 3.31). Several factors were found to influence remission: Treatment with fluoxetine (p? <? 0.0001, OR? =? 3.17, 95% CI 1.80, 5.57), gender (p? =? 0.024, OR? =? 1.90, 95% CI 1.09, 3.30), and number of co-morbid diagnoses (p? =? 0.026, OR 0.73, 95% CI 0.55, 0.96). Conclusion: Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine.

AB - Objective: The aim of this study was to examine the impact of co-morbid illnesses on treatment outcomes in depressed children and adolescents aged 7-17 who were treated with fluoxetine. Method: This data set was drawn from two large clinical trials involving children and adolescents with depression. Subjects with a diagnosis of major depressive disorder and depressive symptoms of at least moderate severity as defined by a Children's Depression Rating Score, Revised (CDRS-R) total score ≥40 and a Clinical Global Impressions-Severity (CGI-S) rating ≥4 were included. Subjects were randomized to receive fluoxetine or placebo over an 8-week period. Predictor analyses examining two primary outcomes were conducted: (1) Response based on Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2, and (2) remission based on CDRS-R score of ≤28. Logistic regression models were run to assess whether anxiety disorders were a predictor of response or remission. Result: A total of 309 study participants were included. The only factor found to influence response was treatment with fluoxetine (p? =? 0.022, odds ratio [OR]? =? 2.08, 95% confidence interval [CI] 1.30, 3.31). Several factors were found to influence remission: Treatment with fluoxetine (p? <? 0.0001, OR? =? 3.17, 95% CI 1.80, 5.57), gender (p? =? 0.024, OR? =? 1.90, 95% CI 1.09, 3.30), and number of co-morbid diagnoses (p? =? 0.026, OR 0.73, 95% CI 0.55, 0.96). Conclusion: Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine.

UR - http://www.scopus.com/inward/record.url?scp=77954914043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954914043&partnerID=8YFLogxK

U2 - 10.1089/cap.2010.0006

DO - 10.1089/cap.2010.0006

M3 - Article

C2 - 20578934

AN - SCOPUS:77954914043

VL - 20

SP - 211

EP - 216

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 3

ER -